Not Yet RecruitingNot Applicable

Analysis of Computed Tomography Derived Maps for Determining Changes of the Liver Volume After Exposure to Radiotherapy

70 participantsStarted 2026-01-01

Plain-language summary

Radiotherapy is commonly used to treat cancers involving the liver or nearby organs. While effective, radiation exposure can affect healthy liver tissue and may lead to changes in liver size and function. Monitoring these changes is important to improve treatment planning and reduce the risk of liver-related complications. This study aims to evaluate changes in liver volume using computed tomography (CT) imaging before and after radiotherapy. By analyzing CT-derived liver maps, the study seeks to better understand how the liver responds to radiation treatment over time. The study will include patients who undergo radiotherapy and have CT imaging performed as part of their routine clinical care. No additional procedures or treatments will be required for participation. The findings of this study may help improve future radiotherapy planning and patient monitoring by providing better information on liver volume changes following radiation exposure.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

1. Inclusion criteria: * Adults aged 18 years or older. * Received radiation therapy (RT) involving the liver (e.g., SBRT, IMRT). The study involves patients in whom the liver was exposed to radiotherapy, either as a direct target (in hepatic-directed treatments as in HCC or liver metastasis) or indirectly as an organ-at-risk (OAR) during irradiation of nearby anatomical regions (as lower lung, gastric, or abdominal sites) where the liver was partially included within the radiation field. The analysis aims to evaluate radiation-induced volumetric changes regardless of whether the liver was the primary target or secondarily affected. * Availability of paired pre- and post-RT CT scans of sufficient quality. * 3D dose distribution data from the RT treatment plan. * Clinical follow-up data, including liver function tests and toxicity records. * No evidence of major anatomical changes between scans unrelated to RT (e.g., surgery). 2. Exclusion criteria: * Patients with a history of major liver surgery (e.g., resection or transplant) between the pre- and post-RT scans. * Presence of severe motion artifacts or poor-quality CT scans that hinder accurate image analysis. * Incomplete or missing 3D radiation dose distribution data. * Lack of sufficient clinical follow-up information (e.g., liver function tests, toxicity outcomes). * Concurrent systemic therapies (e.g., chemotherapy or immunotherapy) during the imaging interval that may confound liv…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Liver Volume After Radiotherapy

Timeframe: Liver volume changes will be assessed at post-treatment intervals, typically at 1, 3, and 6 months after radiotherapy. If only a single post-treatment scan is available, evaluation will occur approximately 3 months after treatment completion.

Trial details

NCT IDNCT07320755

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-01

Contact for this trial

Al Zahraa Ahmed Fouad Hassan, Master Degree

+020-1063704480 zahraa.fouad1998@gmail.com

View on ClinicalTrials.gov More Intra-abdominal Malignancies trials